Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
Hetero is hiring 1 role related to this product
Company
Hetero
India - Hyderabad
RITONAVIR (ritonavir) by Hetero is hiv protease inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection ( ). First approved in 2018.
Drug data last refreshed 18h ago
HIV Protease Inhibitors
Cytochrome P450 3A Inhibitor
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients
Worked on RITONAVIR at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moHetero is hiring 1 role related to this product